DelSite has announced that DelSite Biotechnologies, its wholly-owned subsidiary, has filed an investigational new drug application with the FDA for its lead product candidate GelVac nasal powder H5N1 influenza vaccine.

IRVING, Texas, Aug. 23 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. today announced the issuance of Chinese Patent No. ZL 02807315.0 entitled "In Situ Gel Formation of Pectins" which relates to the Company's proprietary GelSite(R) polymer technology.

DelSite Biotechnologies and Invitrogen Wednesday said they are collaborating on a cell-based bird-flu vaccine.